Cermak Elizabeth

SEC source: 0001437749-25-035177 · rdgdoc.xml · derivative · entry 1

Cermak Elizabeth · CIK 0001471971 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 164,668

Underlying: Common Stock · 150,000 shares

Expires 2035-11-12

F2 · price: The options were issued in connection with the reporting person's Board of Director service to the Company.

F1 · derivative.exercise_date: The options set forth in this table vest on November 12, 2026, subject to the grantee's continued service on the Company's Board of Directors on each vesting date.

SEC source: 0001437749-24-033709 · rdgdoc.xml · derivative · entry 1

Cermak Elizabeth · CIK 0001471971 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,668

Underlying: Common Stock · 10,000 shares

Expires 2034-11-04

F2 · price: The options were issued in connection with the reporting person's Board of Director service to the Company.

F1 · derivative.exercise_date: The options set forth in this table vest through April 2025, subject to the grantee's continued service on the Company's Board of Directors on each vesting date.

SEC source: 0001437749-23-016003 · rdgdoc.xml · derivative · entry 1

Cermak Elizabeth · CIK 0001471971 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,000

Underlying: Common Stock · 15,000 shares

Expires 2033-05-25

F2 · price: The options were issued in connection with the reporting person's Board of Director service to the Company.

F1 · derivative.exercise_date: The options set forth in this table vest on the earlier of one year from the date of the Company's 2023 annual meeting of stockholders or on the next annual meeting of stockholders, subject to the grantee's continued service on the Company's Board of Directors on such vesting date.

SEC source: 0001437749-22-015659 · rdgdoc.xml · derivative · entry 2

Cermak Elizabeth · CIK 0001471971 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,000

Underlying: Common Stock · 15,000 shares

Expires 2032-06-20

F3 · price: The options were issued in connection with the reporting person's Board of Director service to the Company.

F2 · derivative.exercise_date: The options set forth in this table vest on the earlier of one year from the date of the Company's 2022 annual meeting of stockholders or on the date of the next annual meeting of stockholders, subject the grantee's continued service on the Company's Board of Directors on each vesting date.

SEC source: 0001437749-22-015659 · rdgdoc.xml · derivative · entry 1

Cermak Elizabeth · CIK 0001471971 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 23,333 shares

Expires 2032-06-20

F3 · price: The options were issued in connection with the reporting person's Board of Director service to the Company.

F1 · derivative.exercise_date: The options set forth in this table vest in three equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service on the Company's Board of Directors on each vesting date.

SEC source: 0000899243-22-021749 · doc4.xml · derivative · entry 2

Cermak Elizabeth · CIK 0001471971 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,805

Underlying: Common Stock · 4,805 shares

Expires 2032-06-06

F2 · derivative.exercise_date: These options were granted under the 2021 Plan and vest in full at the earlier of June 7, 2023 or the next annual meeting subject to the Reporting Person having a service relationship as of each such vesting.

SEC source: 0000899243-22-021749 · doc4.xml · nonDerivative · entry 1

Cermak Elizabeth · CIK 0001471971 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,766

F1 · shares: The Reporting Person was granted a Restricted Stock Unit under the Issuer's 2021 Stock Option and Incentive Plan (the "2021 Plan") for 1,922 shares on 06/07/2022, which vests in full at the earlier of June 7, 2023 or the next annual meeting subject to the Reporting Person having a service relationship as of each such vesting.

SEC source: 0000899243-21-048208 · doc4.xml · derivative · entry 2

Cermak Elizabeth · CIK 0001471971 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,610

Underlying: Common Stock · 9,610 shares

Expires 2031-12-11

F2 · derivative.exercise_date: These options were granted under the 2021 Plan and vest in equal annual installments over a period of three years from the date of grant subject to the Reporting Person having a service relationship as of each such vesting.

SEC source: 0000899243-21-048208 · doc4.xml · nonDerivative · entry 1

Cermak Elizabeth · CIK 0001471971 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,844

F1 · shares: The Reporting Person was granted a Restricted Stock Unit under the Issuer's 2021 Stock Option and Incentive Plan (the "2021 Plan") for 3,844 shares on 12/12/2021, which vests in equal annual installments over three years from the date of grant subject to the Reporting Person having a service relationship as of each such vesting date.

SEC source: 0001437749-21-014428 · rdgdoc.xml · derivative · entry 1

Cermak Elizabeth · CIK 0001471971 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,667

Underlying: Common Stock · 10,000 shares

Expires 2031-06-07

F2 · price: The options were issued in connection with the reporting person's Board of Director service to the Company.

F1 · derivative.exercise_date: The options set forth in this table vest in four quarterly installments, subject to the grantee's continued service on the Company's Board of Directors on each vesting date.

SEC source: 0001437749-20-020742 · rdgdoc.xml · derivative · entry 1

Cermak Elizabeth · CIK 0001471971 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2030-10-02

F2 · price: The options were issued in connection with the reporting person's Board of Director service to the Company.

F1 · derivative.exercise_date: The options set forth in this table vest in three equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service on the Company's Board of Directors on each vesting date.

SEC source: 0001209191-18-049370 · doc4.xml · derivative · entry 3

Cermak Elizabeth · CIK 0001471971 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 21,029 shares

Expires 2027-12-28

F2 · price: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding in-the-money option, whether vested or unvested, was converted into the right to receive (1) a cash payment equal to (x) the excess, if any, of $4.46 over the exercise price payable under such option, multiplied by (y) the total number of shares subject to such option immediately prior to the Effective Time and (2) a number of CVRs equal to the total number of shares subject to such option immediately prior to the Effective Time.

F2 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding in-the-money option, whether vested or unvested, was converted into the right to receive (1) a cash payment equal to (x) the excess, if any, of $4.46 over the exercise price payable under such option, multiplied by (y) the total number of shares subject to such option immediately prior to the Effective Time and (2) a number of CVRs equal to the total number of shares subject to such option immediately prior to the Effective Time.

SEC source: 0001209191-18-049370 · doc4.xml · derivative · entry 2

Cermak Elizabeth · CIK 0001471971 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 3,875 shares

Expires 2026-10-05

F2 · price: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding in-the-money option, whether vested or unvested, was converted into the right to receive (1) a cash payment equal to (x) the excess, if any, of $4.46 over the exercise price payable under such option, multiplied by (y) the total number of shares subject to such option immediately prior to the Effective Time and (2) a number of CVRs equal to the total number of shares subject to such option immediately prior to the Effective Time.

F2 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding in-the-money option, whether vested or unvested, was converted into the right to receive (1) a cash payment equal to (x) the excess, if any, of $4.46 over the exercise price payable under such option, multiplied by (y) the total number of shares subject to such option immediately prior to the Effective Time and (2) a number of CVRs equal to the total number of shares subject to such option immediately prior to the Effective Time.

SEC source: 0001209191-18-049370 · doc4.xml · derivative · entry 1

Cermak Elizabeth · CIK 0001471971 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 33,350 shares

Expires 2025-08-06

F1 · price: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding out-of-the-money option, whether vested or unvested, was converted into the right to receive a cash payment, if and when the Milestone is achieved, equal to (x) the excess, if any, of the sum of (1) $4.46 and (2) the contingent consideration actually payable per CVR over the exercise price payable under such option, multiplied by (y) the total number of shares subject to such option immediately prior to the Effective Time.

F1 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding out-of-the-money option, whether vested or unvested, was converted into the right to receive a cash payment, if and when the Milestone is achieved, equal to (x) the excess, if any, of the sum of (1) $4.46 and (2) the contingent consideration actually payable per CVR over the exercise price payable under such option, multiplied by (y) the total number of shares subject to such option immediately prior to the Effective Time.

SEC source: 0001209191-17-067545 · doc4.xml · derivative · entry 2

Cermak Elizabeth · CIK 0001471971 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,000

Underlying: Ordinary Shares · 8,000 shares

Expires 2027-12-28

F1 · derivative.exercise_date: 1/3rd of the Option Shares shall vest on the first anniversary of the grant date. Thereafter, the remaining balance of the Option Shares shall vest in a series of 8 equal consecutive quarterly installments until fully vested.

SEC source: 0001209191-17-067545 · doc4.xml · derivative · entry 1

Cermak Elizabeth · CIK 0001471971 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,029

Underlying: Ordinary Shares · 13,029 shares

Expires 2027-12-28

F1 · derivative.exercise_date: 1/3rd of the Option Shares shall vest on the first anniversary of the grant date. Thereafter, the remaining balance of the Option Shares shall vest in a series of 8 equal consecutive quarterly installments until fully vested.

SEC source: 0001209191-16-145118 · doc4.xml · derivative · entry 1

Cermak Elizabeth · CIK 0001471971 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,875

Underlying: Common Stock · 3,875 shares

Expires 2026-10-05

F1 · derivative.exercise_date: 1/3rd of the Option Shares shall vest on the first anniversary of the grant date. Thereafter, the remaining balance of the Option Shares shall vest in a series of 8 equal consecutive quarterly installments until fully vested.